{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T21:13:35Z","timestamp":1760044415501},"reference-count":52,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.3892\/or.2017.5476","type":"journal-article","created":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T02:16:30Z","timestamp":1487902590000},"page":"2295-2307","source":"Crossref","is-referenced-by-count":4,"title":["pSTAT5 and ERK exhibit different expression in myeloproliferative neoplasms"],"prefix":"10.3892","volume":"37","author":[{"given":"Ewa","family":"Wi\u015bniewska-Chudy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0141ukasz","family":"Szylberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz","family":"Dworacki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Mizera-Nyczak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Marsza\u0142ek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2249","published-online":{"date-parts":[[2017,2,24]]},"reference":[{"key":"key20180107224342_b1-or-37-04-2295","doi-asserted-by":"crossref","first-page":"2911","DOI":"10.1200\/JCO.2008.17.5745","article-title":"Chronic myeloid leukemia stem cells","volume":"26","author":"Kavalerchik","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20180107224342_b2-or-37-04-2295","doi-asserted-by":"crossref","first-page":"3863","DOI":"10.1182\/blood-2007-09-111971","article-title":"Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations","volume":"111","author":"Li","year":"2008","journal-title":"Blood"},{"key":"key20180107224342_b3-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.leukres.2009.01.034","article-title":"A myeloproliferative disorder may hide another one","volume":"33","author":"Laibe","year":"2009","journal-title":"Leuk Res"},{"key":"key20180107224342_b4-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1182\/blood-2008-02-138230","article-title":"The natural history and treatment outcome of blast phase BCR-ABL- myeloproliferative neoplasms","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"key20180107224342_b5-or-37-04-2295","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1182\/blood-2009-03-210039","article-title":"Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies","volume":"114","author":"Abdel-Wahab","year":"2009","journal-title":"Blood"},{"key":"key20180107224342_b6-or-37-04-2295","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1056\/NEJMra063728","article-title":"The myeloproliferative disorders","volume":"355","author":"Campbell","year":"2006","journal-title":"N Engl J Med"},{"key":"key20180107224342_b7-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"key20180107224342_b8-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107224342_b9-or-37-04-2295","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"key20180107224342_b10-or-37-04-2295","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"key20180107224342_b11-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"key20180107224342_b12-or-37-04-2295","doi-asserted-by":"crossref","first-page":"16651","DOI":"10.1074\/jbc.M109.071191","article-title":"Activation of JAK2-V617F by components of heterodimeric cytokine receptors","volume":"285","author":"Pradhan","year":"2010","journal-title":"J Biol Chem"},{"key":"key20180107224342_b13-or-37-04-2295","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1097\/MD.0b013e31815d108c","article-title":"Management of hypereosinophilic syndrome: A prospective study in the era of molecular genetics","volume":"86","author":"Dahabreh","year":"2007","journal-title":"Medicine (Baltimore)"},{"key":"key20180107224342_b14-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1016\/j.leukres.2007.12.007","article-title":"Hypereosinophilic syndrome: Another face of janus?","volume":"32","author":"Dahabreh","year":"2008","journal-title":"Leuk Res"},{"key":"key20180107224342_b15-or-37-04-2295","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"key20180107224342_b16-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u2018atypical myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"key20180107224342_b17-or-37-04-2295","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"key20180107224342_b18-or-37-04-2295","doi-asserted-by":"crossref","first-page":"6724","DOI":"10.1038\/sj.onc.1210757","article-title":"Hematopoietic cytokine receptor signaling","volume":"26","author":"Baker","year":"2007","journal-title":"Oncogene"},{"key":"key20180107224342_b19-or-37-04-2295","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1146\/annurev.med.59.061506.154159","article-title":"A role for JAK2 mutations in myeloproliferative diseases","volume":"59","author":"Morgan","year":"2008","journal-title":"Annu Rev Med"},{"key":"key20180107224342_b20-or-37-04-2295","doi-asserted-by":"crossref","first-page":"4274","DOI":"10.1182\/blood-2005-12-4824","article-title":"Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model","volume":"107","author":"Wernig","year":"2006","journal-title":"Blood"},{"key":"key20180107224342_b21-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2006-02-002030","article-title":"JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis","volume":"108","author":"Lacout","year":"2006","journal-title":"Blood"},{"key":"key20180107224342_b22-or-37-04-2295","doi-asserted-by":"crossref","first-page":"3931","DOI":"10.1182\/blood-2007-08-107748","article-title":"Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice","volume":"111","author":"Tiedt","year":"2008","journal-title":"Blood"},{"key":"key20180107224342_b23-or-37-04-2295","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/sj.leu.2405043","article-title":"Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F","volume":"22","author":"Shide","year":"2008","journal-title":"Leukemia"},{"key":"key20180107224342_b24-or-37-04-2295","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.leu.2404206","article-title":"JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained","volume":"20","author":"Steensma","year":"2006","journal-title":"Leukemia"},{"key":"key20180107224342_b25-or-37-04-2295","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/sj.leu.2404086","article-title":"JAK2 V617F mutation in classic chronic myeloproliferative diseases: A report on a series of 349 patients","volume":"20","author":"Vizmanos","year":"2006","journal-title":"Leukemia"},{"key":"key20180107224342_b26-or-37-04-2295","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood-2009-04-215848","article-title":"Conditional expression of heterozygous or homozygous Jak2V617F from its endogenous promoter induces a polycythemia vera-like disease","volume":"115","author":"Akada","year":"2010","journal-title":"Blood"},{"key":"key20180107224342_b27-or-37-04-2295","doi-asserted-by":"crossref","first-page":"236","DOI":"10.4132\/jptm.2015.03.16","article-title":"Proposal of an appropriate decalcification method of bone marrow biopsy specimens in the era of expanding genetic molecular study","volume":"49","author":"Choi","year":"2015","journal-title":"J Pathol Transl Med"},{"key":"key20180107224342_b28-or-37-04-2295","doi-asserted-by":"crossref","first-page":"e115558","DOI":"10.1371\/journal.pone.0115558","article-title":"PARP-1 expression is increased in colon adenoma and carcinoma and correlates with OGG1","volume":"9","author":"Dziaman","year":"2014","journal-title":"PLoS One,"},{"key":"key20180107224342_b29-or-37-04-2295","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hed.23618","article-title":"Expression of metalloproteinases 2 and 9 and tissue inhibitors 1 and 2 as predictors of lymph node metastases in oropharyngeal squamous cell carcinoma","volume":"37","author":"Burduk","year":"2015","journal-title":"Head Neck"},{"key":"key20180107224342_b30-or-37-04-2295","first-page":"138","article-title":"Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue","volume":"8","author":"Remmele","year":"1987","journal-title":"Pathologe"},{"key":"key20180107224342_b31-or-37-04-2295","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1093\/nar\/29.9.e45","article-title":"A new mathematical model for relative quantification in real-time RT-PCR","volume":"29","author":"Pfaffl","year":"2001","journal-title":"Nucleic Acids Res"},{"key":"key20180107224342_b32-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1038\/sj.leu.2404292","article-title":"The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors","volume":"20","author":"Sidon","year":"2006","journal-title":"Leukemia"},{"key":"key20180107224342_b33-or-37-04-2295","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"key20180107224342_b34-or-37-04-2295","doi-asserted-by":"crossref","first-page":"e270","DOI":"10.1371\/journal.pmed.0030270","article-title":"MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia","volume":"3","author":"Pikman","year":"2006","journal-title":"PLoS Med"},{"key":"key20180107224342_b35-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"key20180107224342_b36-or-37-04-2295","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: A study of 1182 patients","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"key":"key20180107224342_b37-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/leu.2008.137","article-title":"New mutations of MPL in primitive myelofibrosis: Only the MPL W515 mutations promote a G1\/S-phase transition.","volume":"22","author":"Chalign\u00e9","year":"2008","journal-title":"Leukemia"},{"key":"key20180107224342_b38-or-37-04-2295","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: Analysis of the PT-1 cohort","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"key":"key20180107224342_b39-or-37-04-2295","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1111\/j.1365-2141.2010.08083.x","article-title":"Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombocythaemia and primary myelofibrosis","volume":"149","author":"Boyd","year":"2010","journal-title":"Br J Haematol"},{"key":"key20180107224342_b40-or-37-04-2295","doi-asserted-by":"crossref","first-page":"16","DOI":"10.5315\/wjh.v4.i3.16","article-title":"European vs 2015-World Health Organization clinical molecular and pathological classification of myeloproliferative neoplasms","volume":"4","author":"Michiels","year":"2015","journal-title":"World J Hematol"},{"key":"key20180107224342_b41-or-37-04-2295","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/j.clml.2014.06.014","article-title":"Myeloproliferative neoplasms: JAK2 signaling pathway as a central target for therapy","volume":"14","author":"Pasquier","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"key20180107224342_b42-or-37-04-2295","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.gde.2006.12.009","article-title":"Jak2: Normal function and role in hematopoietic disorders","volume":"17","author":"Ihle","year":"2007","journal-title":"Curr Opin Genet Dev"},{"key":"key20180107224342_b43-or-37-04-2295","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0092-8674(00)81277-5","article-title":"STATs: Signal transducers and activators of transcription","volume":"84","author":"Ihle","year":"1996","journal-title":"Cell"},{"key":"key20180107224342_b44-or-37-04-2295","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0303-7207(97)00164-0","article-title":"Mitogen-activated protein kinase kinase inhibition decreases growth hormone stimulated transcription mediated by STAT5","volume":"133","author":"Pircher","year":"1997","journal-title":"Mol Cell Endocrinol"},{"key":"key20180107224342_b45-or-37-04-2295","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1210\/mend.13.4.0263","article-title":"Extracellular signal-regulated kinase (ERK) interacts with signal transducer and activator of transcription (STAT) 5a","volume":"13","author":"Pircher","year":"1999","journal-title":"Mol Endocrinol"},{"key":"key20180107224342_b46-or-37-04-2295","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1158\/1078-0432.CCR-07-0524","article-title":"WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation","volume":"14","author":"Verstovsek","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20180107224342_b47-or-37-04-2295","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/01.pas.0000213338.25111.d3","article-title":"Bone marrow phospho-STAT5 expression in non-CML chronic myeloproliferative disorders correlates with JAK2 V617F mutation and provides evidence of in vivo JAK2 activation","volume":"31","author":"Aboudola","year":"2007","journal-title":"Am J Surg Pathol"},{"key":"key20180107224342_b48-or-37-04-2295","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1042\/BJ20041523","article-title":"Activated STAT5 proteins induce activation of the PI 3-kinase\/Akt and Ras\/MAPK pathways via the Gab2 scaffolding adapter","volume":"390","author":"Nyga","year":"2005","journal-title":"Biochem J"},{"key":"key20180107224342_b49-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/sj.onc.1203418","article-title":"Cooperation between STAT5 and phosphatidylinositol 3-kinase in the IL-3-dependent survival of a bone marrow derived cell line","volume":"19","author":"Rosa","year":"2000","journal-title":"Oncogene"},{"key":"key20180107224342_b50-or-37-04-2295","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.humpath.2007.10.034","article-title":"Phospho-STAT5 expression pattern with the MPL W515L mutation is similar to that seen in chronic myeloproliferative disorders with JAK2 V617F","volume":"39","author":"Gibson","year":"2008","journal-title":"Hum Pathol"},{"key":"key20180107224342_b51-or-37-04-2295","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1111\/j.1365-2141.2009.07870.x","article-title":"Phospho-STAT5 and phospho-Akt expression in chronic myeloproliferative neoplasms","volume":"147","author":"Grimwade","year":"2009","journal-title":"Br J Haematol"},{"key":"key20180107224342_b52-or-37-04-2295","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/nrm909","article-title":"Stats: Transcriptional control and biological impact","volume":"3","author":"Levy","year":"2002","journal-title":"Nat Rev Mol Cell Biol"}],"container-title":["Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/spandidos-publications.com\/10.3892\/or.2017.5476\/download","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2018,1,7]],"date-time":"2018-01-07T17:55:59Z","timestamp":1515347759000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/or.2017.5476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,24]]},"references-count":52,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,2,24]]},"published-print":{"date-parts":[[2017,3]]}},"alternative-id":["10.3892\/or.2017.5476"],"URL":"https:\/\/doi.org\/10.3892\/or.2017.5476","relation":{},"ISSN":["1021-335X","1791-2431"],"issn-type":[{"value":"1021-335X","type":"print"},{"value":"1791-2431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,24]]}}}